Silveira Gislaine G O S, Torres Marcelo D T, Ribeiro Camila F A, Meneguetti Beatriz T, Carvalho Cristiano M E, de la Fuente-Nunez Cesar, Franco Octávio L, Cardoso Marlon H
S-Inova Biotech, Programa de Pós-Graduação Stricto Sensu em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande, Mato Grosso do Sul 79117-010, Brazil.
Machine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
ACS Pharmacol Transl Sci. 2021 Jan 27;4(1):55-73. doi: 10.1021/acsptsci.0c00191. eCollection 2021 Feb 12.
Biofilm-forming bacteria may be 10-1000 times more resistant to antibiotics than planktonic bacteria and represent about 75% of bacterial infections in humans. Antibiofilm treatments are scarce, and no effective therapies have been reported so far. In this context, antibiofilm peptides (ABPs) represent an exciting class of agents with potent activity against biofilms both and . Moreover, murine models of bacterial biofilm infections have been used to evaluate the effectiveness of ABPs. Therefore, here we highlight the translational potential of ABPs and provide an overview of the different clinically relevant murine models to assess ABP efficacy, including wound, foreign body, chronic lung, and oral models of infection. We discuss key challenges to translate ABPs to the clinic and the pros and cons of the existing murine biofilm models for reliable assessment of the efficacy of ABPs.
形成生物膜的细菌对抗生素的耐药性可能比浮游细菌高10到1000倍，约占人类细菌感染的75%。抗生物膜治疗方法稀缺，目前尚无有效疗法的报道。在此背景下，抗生物膜肽（ABP）是一类令人兴奋的药物，对生物膜具有强大的活性。此外，细菌生物膜感染的小鼠模型已被用于评估ABP的有效性。因此，我们在此强调ABP的转化潜力，并概述不同的临床相关小鼠模型，以评估ABP的疗效，包括伤口、异物、慢性肺部和口腔感染模型。我们讨论了将ABP转化到临床的关键挑战，以及现有小鼠生物膜模型在可靠评估ABP疗效方面的优缺点。
